Effects of Tezepelumab on Quality of Life of Patients with Moderate-to-Severe, Uncontrolled Asthma: Systematic Review and Meta-Analysis

Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Published 2022. Accessed 18 Nov 2022. https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf.

• Edris A, De Feyter S, Maes T, Joos G, Lahousse L. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. Respir Res. 2019;20(1):179. https://doi.org/10.1186/s12931-019-1138-3. This article evaluates new biologic agents for persistently uncontrolled asthma and compares their effects on asthma exacerbation rate.

Article  PubMed  PubMed Central  Google Scholar 

•• Pelaia C, Pelaia G, Crimi C, et al. Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma. Int J Mol Sci. 2021;22(9). https://doi.org/10.3390/ijms22094369. This article reviews the role of thymic stromal lymphopoietin in the pathogenesis of asthma and the rationale for the use of tezepelumab as an add-on therapy for severe, uncontrolled asthma.

Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777–92. https://doi.org/10.1080/14728222.2020.1783242.

Article  CAS  PubMed  Google Scholar 

Corren J, Parnes JR, Wang L, et al. Tezepelumab in Adults with Uncontrolled Asthma (PATHWAY). N Engl J Med. 2017;377(10):936–46. https://doi.org/10.1056/NEJMoa1704064.

Article  CAS  PubMed  Google Scholar 

Rich HE, Antos D, Melton NR, Alcorn JF, Manni ML. Insights Into Type I and III Interferons in Asthma and Exacerbations. Front Immunol. 2020;11:574027. https://doi.org/10.3389/fimmu.2020.574027.

Corren J, Garcia Gil E, Griffiths JM, et al. Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. Ann Allergy Asthma Immunol. 2021;126(2):187–93. https://doi.org/10.1016/j.anai.2020.10.008.

Article  CAS  PubMed  Google Scholar 

Marone G, Spadaro G, Braile M, et al. Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma. Expert Opin Investig Drugs. 2019;28(11):931–40. https://doi.org/10.1080/13543784.2019.1672657.

Article  CAS  PubMed  Google Scholar 

Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma (NAVIGATOR). N Engl J Med. 2021;384(19):1800–9. https://doi.org/10.1056/NEJMoa2034975.

Article  CAS  PubMed  Google Scholar 

Feist J, Lipari M, Kale-Pradhan P. Tezepelumab in the Treatment of Uncontrolled Severe Asthma. Ann Pharmacother. 2023;57(1):62–70. https://doi.org/10.1177/10600280221095540.

Article  CAS  PubMed  Google Scholar 

Matera MG, Rogliani P, Calzetta L, Cazzola M. TSLP Inhibitors for Asthma: Current Status and Future Prospects. Drugs. 2020;80(5):449–58. https://doi.org/10.1007/s40265-020-01273-4.

Article  CAS  PubMed  Google Scholar 

Wechsler ME, Menzies-Gow A, Brightling CE, et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir Med. 2022;10(7):650–60. https://doi.org/10.1016/S2213-2600(21)00537-3.

Article  CAS  PubMed  Google Scholar 

Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. editors. Cochrane handbook for systematic reviews of interventions version 6.3. (Updated February 2022). Cochrane; 2022.

Page M, Moher D, Bossuyt P, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372(160). https://doi.org/10.1136/bmj.n160.

Chagas G, Xavier D, Gomes L, Ferri-Guerra J, Oquet R. The Effects of Tezepelumab on The Quality of Life of Patients with Moderate-to-Severe, Uncontrolled Asthma: A Systematic Review and Meta-Analysis. PROSPERO. Published 2022. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=361442.

Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898.

Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. https://doi.org/10.1002/sim.1186.

Article  PubMed  Google Scholar 

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557 LP-560. https://doi.org/10.1136/bmj.327.7414.557.

Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. https://doi.org/10.1136/bmj.d4002.

Schünemann H, Brożek J, Guyatt G, Oxman A. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. (The GRADE Working Group, ed.). 2013. https://guidelinedevelopment.org/handbook.

Bonini M, Di Paolo M, Bagnasco D, et al. Minimal clinically important difference for asthma endpoints: an expert consensus report. Eur Respir Rev Off J Eur Respir Soc. 2020;29(156). https://doi.org/10.1183/16000617.0137-2019.

Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47(1):81–7. https://doi.org/10.1016/0895-4356(94)90036-1.

Article  CAS  PubMed  Google Scholar 

Globe G, Wiklund I, Mattera M, Zhang H, Revicki DA. Evaluating minimal important differences and responder definitions for the asthma symptom diary in patients with moderate to severe asthma. J Patient-Rep Outcomes. 2019;3(1):22. https://doi.org/10.1186/s41687-019-0109-2.

Article  PubMed  PubMed Central  Google Scholar 

Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111–24. https://doi.org/10.1081/copd-200053377.

Article  PubMed  Google Scholar 

Oppenheimer J, Hoyte FCL, Phipatanakul W, Silver J, Howarth P, Lugogo NL. Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions. Ann Allergy Asthma Immunol. 2022;129(2):169–80. https://doi.org/10.1016/j.anai.2022.02.021.

Article  CAS  PubMed  Google Scholar 

Frey U, Brodbeck T, Majumdar A, et al. Risk of severe asthma episodes predicted from fluctuation analysis of airway function. Nature. 2005;438(7068):667–70. https://doi.org/10.1038/nature04176.

Article  CAS  PubMed  Google Scholar 

Menzies-Gow A, Steenkamp J, Singh S, et al. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. J Med Econ. 2022;25(1):679–90. https://doi.org/10.1080/13696998.2022.2074195.

Article  PubMed  Google Scholar 

Pitre T, Jassal T, Angjeli A, et al. A comparison of the effectiveness of biologic therapies for asthma: a systematic review and network meta-analysis. Ann Allergy Asthma Immunol Off Publ Am Coll. Published online December 2022. https://doi.org/10.1016/j.anai.2022.12.018.

Nopsopon T, Lassiter G, Chen M-L, et al. Comparative Efficacy of Tezepelumab to Mepolizumab, Benralizumab, and Dupilumab in Eosinophilic Asthma: A Bayesian Network Meta-analysis. J Allergy Clin Immunol Published online. 2022. https://doi.org/10.1016/j.jaci.2022.11.021.

Article  Google Scholar 

Shaban Abdelgalil M, Ahmed Elrashedy A, Awad AK, et al. Safety and efficacy of tezepelumab vs. placebo in adult patients with severe uncontrolled asthma: a systematic review and meta-analysis. Sci Rep. 2022;12(1):20905. https://doi.org/10.1038/s41598-022-24763-9.

Zoumot Z, Al Busaidi N, Tashkandi W, et al. Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis. J Asthma Allergy. 2022;15:1665–79. https://doi.org/10.2147/JAA.S378062.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ando K, Fukuda Y, Tanaka A, Sagara H. Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis. Cells. 2022;11(5). https://doi.org/10.3390/cells11050819.

U.S. Food and Drug Administration. FDA approves maintenance treatment for severe asthma. Published 2021. Accessed 1 Jan 2023. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-maintenance-treatment-severe-asthma.

Tay TR, Pham J, Hew M. Addressing the impact of ethnicity on asthma care. Curr Opin Allergy Clin Immunol. 2020;20(3):274–81. https://doi.org/10.1097/ACI.0000000000000609.

Article  PubMed  Google Scholar 

留言 (0)

沒有登入
gif